Skip to main content
Top
Published in: Addiction Science & Clinical Practice 1/2017

Open Access 01-12-2017 | Commentary

More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic

Authors: Peter D. Friedmann, Joji Suzuki

Published in: Addiction Science & Clinical Practice | Issue 1/2017

Login to get access

Excerpt

Given extensive research evidence that pharmacotherapy is the most effective treatment for opioid use disorder (OUD), and the unabating rise in opioid overdose deaths, it is increasingly apparent that detoxification and “drug-free” treatment should be replaced by medication induction and long-term pharmacotherapy as the first-line standard of care. Nonetheless, calls for more “treatment beds” are heard in the political and public health discourse surrounding interventions to address the epidemic of opioid overdose deaths. States seek federal Medicaid waivers to expand treatment beds, and legislatures increase funding for state-sponsored beds. The term “beds” is usually shorthand for detoxification beds, short-term inpatient or residential beds, and may include outpatient treatment with beds in sober housing, but it usually does not refer to slots in opioid treatment programs or other settings that utilize effective medication treatment for opioid use disorder (OUD). To access these “beds”, patients with OUD first undergo detoxification, whether in an inpatient detoxification program, jail or hospital, and are then discharged to these settings where they receive monitoring, psychosocial support and counseling, but typically no effective medication. …
Literature
1.
go back to reference Bisaga A, Sullivan MA. Death by detoxification. Huffington Post; 2013. Bisaga A, Sullivan MA. Death by detoxification. Huffington Post; 2013.
3.
go back to reference Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O’Grady KE, Jaffe JH. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89–95.CrossRefPubMedPubMedCentral Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O’Grady KE, Jaffe JH. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89–95.CrossRefPubMedPubMedCentral
4.
go back to reference Betty Ford Institute Consensus P. What is recovery? A working definition from the Betty Ford Institute. J Subst Abuse Treat. 2007;33(3):221–8.CrossRef Betty Ford Institute Consensus P. What is recovery? A working definition from the Betty Ford Institute. J Subst Abuse Treat. 2007;33(3):221–8.CrossRef
5.
go back to reference Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.CrossRefPubMedPubMedCentral Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.CrossRefPubMedPubMedCentral
6.
go back to reference Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ. 2003;326(7396):959–60.CrossRefPubMedPubMedCentral Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ. 2003;326(7396):959–60.CrossRefPubMedPubMedCentral
7.
go back to reference Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–8.CrossRefPubMed Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–8.CrossRefPubMed
8.
go back to reference Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7(3):249–56.CrossRefPubMed Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7(3):249–56.CrossRefPubMed
9.
go back to reference Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend. 2000;58(1–2):85–92.CrossRefPubMed Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend. 2000;58(1–2):85–92.CrossRefPubMed
10.
go back to reference Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML. One-, three-, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse. 2001;27(1):19–44.CrossRefPubMed Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML. One-, three-, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse. 2001;27(1):19–44.CrossRefPubMed
11.
go back to reference Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry. 1989;154:348–53.CrossRefPubMed Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry. 1989;154:348–53.CrossRefPubMed
12.
go back to reference Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.CrossRefPubMedPubMedCentral Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.CrossRefPubMedPubMedCentral
13.
go back to reference Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303–10.CrossRefPubMed Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303–10.CrossRefPubMed
14.
go back to reference Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223–7.CrossRefPubMed Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223–7.CrossRefPubMed
15.
go back to reference Senay EC, Dorus W, Showalter CV. Short-term detoxification with methadone. Ann NY Acad Sci. 1981;362:203–16.CrossRefPubMed Senay EC, Dorus W, Showalter CV. Short-term detoxification with methadone. Ann NY Acad Sci. 1981;362:203–16.CrossRefPubMed
16.
go back to reference Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2(8141):485–8.CrossRefPubMed Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2(8141):485–8.CrossRefPubMed
17.
go back to reference Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–46.CrossRefPubMedPubMedCentral Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–46.CrossRefPubMedPubMedCentral
18.
go back to reference Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O’Connor PG, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–74.CrossRefPubMed Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O’Connor PG, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–74.CrossRefPubMed
19.
go back to reference Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–42.CrossRefPubMedPubMedCentral Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–42.CrossRefPubMedPubMedCentral
20.
go back to reference Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, et al. Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. J Subst Abuse Treat. 2017. Epub ahead of print. Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, et al. Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. J Subst Abuse Treat. 2017. Epub ahead of print.
21.
go back to reference Clark RE, Baxter JD, Aweh G, O’Connell E, Fisher WH, Barton BA. risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75–80.CrossRefPubMedPubMedCentral Clark RE, Baxter JD, Aweh G, O’Connell E, Fisher WH, Barton BA. risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75–80.CrossRefPubMedPubMedCentral
22.
go back to reference Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017;11:286–92.CrossRefPubMedPubMedCentral Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017;11:286–92.CrossRefPubMedPubMedCentral
Metadata
Title
More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic
Authors
Peter D. Friedmann
Joji Suzuki
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Addiction Science & Clinical Practice / Issue 1/2017
Electronic ISSN: 1940-0640
DOI
https://doi.org/10.1186/s13722-017-0092-y

Other articles of this Issue 1/2017

Addiction Science & Clinical Practice 1/2017 Go to the issue